Titre
Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Du Pasquier, R.A.
Auteure/Auteur
Jilek, S.
Auteure/Auteur
Kalubi, M.
Auteure/Auteur
Yerly, S.
Auteure/Auteur
Fux, C.A.
Auteure/Auteur
Gutmann, C.
Auteure/Auteur
Cusini, A.
Auteure/Auteur
Günthard, H.F.
Auteure/Auteur
Cavassini, M.
Auteure/Auteur
Vernazza, P.L.
Auteure/Auteur
Contributrices/contributeurs
Aubert, V.
Barth, J.
Battegay, M.
Bernasconi, E.
Böni, J.
Bucher, HC.
Burton-Jeangros, C.
Calmy, A.
Cavassini, M.
Egger, M.
Elzi, L.
Fehr, J.
Fellay, J.
Flepp, M.
Francioli, P.
Furrer, H.
Fux, CA.
Gorgievski, M.
Günthard, H.
Haerry, D.
Hasse, B.
Hirsch, HH.
Hirschel, B.
Hösli, I.
Kahlert, C.
Kaiser, L.
Keiser, O.
Kind, C.
Klimkait, T.
Kovari, H.
Ledergerber, B.
Martinetti, G.
Martinez de Tejada, B.
Metzner, K.
Müller, N.
Nadal, D.
Pantaleo, G.
Rauch, A.
Regenass, S.
Rickenbach, M.
Rudin, C.
Schmid, P.
Schultze, D.
Schöni-Affolter, F.
Speck, R.
Taffé, P.
Tarr, P.
Telenti, A.
Trkola, A.
Vernazza, P.
Weber, R.
Yerly, S.
Groupes de travail
Swiss HIV Cohort Study
Liens vers les personnes
Liens vers les unités
ISSN
1473-5571
Statut éditorial
Publié
Date de publication
2013
Volume
27
Numéro
2
Première page
203
Dernière page/numéro d’article
210
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
OBJECTIVE: To determine changes of cerebrospinal fluid (CSF) biomarkers of patients on monotherapy with lopinavir/ritonavir.
DESIGN: The Monotherapy Switzerland/Thailand study (MOST) trial compared monotherapy with ritonavir-boosted lopinavir with continued therapy. The trial was prematurely stopped due to virological failure in six patients on monotherapy. It, thus, offers a unique opportunity to assess brain markers in the early stage of HIV virological escape.
METHODS: : Sixty-five CSF samples (34 on continued therapy and 31 on monotherapy) from 49 HIV-positive patients enrolled in MOST. Using enzyme-linked immunosorbent assay, we determined the CSF concentration of S100B (astrocytosis), neopterin (inflammation), total Tau (tTau), phosphorylated Tau (pTau), and amyloid-β 1-42 (Aβ), the latter three indicating neuronal damage. Controls were CSF samples of 29 HIV-negative patients with Alzheimer dementia.
RESULTS: In the CSF of monotherapy, concentrations of S100B and neopterin were significantly higher than in continued therapy (P = 0.006 and P = 0.013, respectively) and Alzheimer dementia patients (P < 0.0001 and P = 0.0005, respectively). In Alzheimer dementia, concentration of Aβ was lower than in monotherapy (P = 0.005) and continued therapy (P = 0.016) and concentrations of tTau were higher than in monotherapy (P = 0.019) and continued therapy (P = 0.001). There was no difference in pTau among the three groups. After removal of the 16 CSF with detectable viral load in the blood and/or CSF, only S100B remained significantly higher in monotherapy than in the two other groups.
CONCLUSION: Despite full viral load-suppression in blood and CSF, antiretroviral monotherapy with lopinavir/ritonavir can raise CSF levels of S100B, suggesting astrocytic damage.
DESIGN: The Monotherapy Switzerland/Thailand study (MOST) trial compared monotherapy with ritonavir-boosted lopinavir with continued therapy. The trial was prematurely stopped due to virological failure in six patients on monotherapy. It, thus, offers a unique opportunity to assess brain markers in the early stage of HIV virological escape.
METHODS: : Sixty-five CSF samples (34 on continued therapy and 31 on monotherapy) from 49 HIV-positive patients enrolled in MOST. Using enzyme-linked immunosorbent assay, we determined the CSF concentration of S100B (astrocytosis), neopterin (inflammation), total Tau (tTau), phosphorylated Tau (pTau), and amyloid-β 1-42 (Aβ), the latter three indicating neuronal damage. Controls were CSF samples of 29 HIV-negative patients with Alzheimer dementia.
RESULTS: In the CSF of monotherapy, concentrations of S100B and neopterin were significantly higher than in continued therapy (P = 0.006 and P = 0.013, respectively) and Alzheimer dementia patients (P < 0.0001 and P = 0.0005, respectively). In Alzheimer dementia, concentration of Aβ was lower than in monotherapy (P = 0.005) and continued therapy (P = 0.016) and concentrations of tTau were higher than in monotherapy (P = 0.019) and continued therapy (P = 0.001). There was no difference in pTau among the three groups. After removal of the 16 CSF with detectable viral load in the blood and/or CSF, only S100B remained significantly higher in monotherapy than in the two other groups.
CONCLUSION: Despite full viral load-suppression in blood and CSF, antiretroviral monotherapy with lopinavir/ritonavir can raise CSF levels of S100B, suggesting astrocytic damage.
PID Serval
serval:BIB_53A5510C85E2
PMID
Date de création
2013-01-17T17:09:09.283Z
Date de création dans IRIS
2025-05-20T20:49:47Z